Published in J Transl Med on September 13, 2011
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One (2012) 0.88
Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci (2014) 0.87
Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.78
Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology (2015) 0.78
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int J Mol Sci (2016) 0.76
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. Cancer Immunol Immunother (2017) 0.75
Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications. Stem Cells Int (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Taking dendritic cells into medicine. Nature (2007) 11.82
Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol (1995) 10.65
TLR signaling. Semin Immunol (2007) 8.16
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity (1998) 4.85
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
Antiviral signaling through pattern recognition receptors. J Biochem (2006) 3.84
Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol (2005) 3.75
A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med (2005) 3.59
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol (2003) 2.68
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A (2004) 2.58
The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A (2008) 2.57
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood (2007) 2.29
APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (2007) 2.28
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol (2003) 2.08
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood (2009) 1.90
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc Natl Acad Sci U S A (2004) 1.80
In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65
Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol (2006) 1.63
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood (2002) 1.62
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol (2009) 1.31
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med (2007) 1.30
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica (2010) 1.27
Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol (2008) 1.27
TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res (2011) 1.15
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol (2010) 1.11
Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program (2009) 1.10
Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans (2007) 0.98
Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher (2004) 0.90
Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods (2008) 0.86
Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol (2008) 0.81
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Structures of the human and Drosophila 80S ribosome. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell (2012) 2.15
Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol (2007) 2.10
Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res (2006) 1.92
Graft-versus-leukemia reactions in allogeneic chimeras. Blood (2003) 1.84
Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol (2012) 1.68
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol (2005) 1.37
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood (2010) 1.35
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med (2007) 1.30
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest (2010) 1.30
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood (2013) 1.16
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol (2009) 1.15
Designer T cells by T cell receptor replacement. Eur J Immunol (2006) 1.14
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol (2010) 1.11
NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol (2002) 1.10
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood (2009) 1.10
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. J Allergy Clin Immunol (2005) 1.07
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood (2012) 1.05
Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. EMBO J (2003) 1.04
Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women. J Allergy Clin Immunol (2007) 1.04
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01
Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes (2006) 0.98
Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol (2011) 0.97
Immune suppression in renal cell carcinoma. Semin Cancer Biol (2007) 0.97
CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells (2013) 0.96
A role for MCP-1/CCR2 in interstitial lung disease in children. Respir Res (2005) 0.95
Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther (2006) 0.94
Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer (2003) 0.93
Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med (2010) 0.92
Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol (2006) 0.92
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res (2010) 0.91
Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther (2005) 0.91
Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther (2009) 0.90
Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity--a randomized, double-blind, placebo-controlled study. Am J Clin Nutr (2007) 0.90
The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion. J Innate Immun (2010) 0.89
Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol (2008) 0.88
MBP-PLP fusion protein-induced EAE in C57BL/6 mice. J Neuroimmunol (2006) 0.88
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol (2012) 0.88
CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One (2012) 0.88
Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol (2014) 0.87
Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma. Leuk Res (2012) 0.86
NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med (2012) 0.86
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther (2010) 0.85
TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I. Eur J Immunol (2006) 0.85
Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med (2007) 0.85
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol Med (2013) 0.84
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology (2012) 0.84
RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol Ther (2005) 0.84
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol (2005) 0.83
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J Transl Med (2005) 0.83
Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol (2006) 0.83
Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety. J Immunother (2007) 0.83
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res (2005) 0.82
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma (2010) 0.82
Association between levels of Toll-like receptors 2 and 4 and CD14 mRNA and allergy in pregnant women and their offspring. Clin Immunol (2005) 0.81
Immunotherapy of lung cancer: an update. Onkologie (2006) 0.81
Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J Immunother (2008) 0.81
Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy (2013) 0.80
Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med (Berl) (2009) 0.80
Frequency of Valpha24+CD161+ natural killer T cells and invariant TCRAV24-AJ18 transcripts in atopic and non-atopic individuals. Immunobiology (2003) 0.80
Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. PLoS One (2009) 0.79
Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. Mol Ther (2005) 0.78
New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother (2014) 0.78
High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find them. Oncoimmunology (2012) 0.77
Antigen presenting cells transfected with LMP2a RNA induce CD4+ LMP2a-specific cytotoxic T lymphocytes which kill via a Fas-independent mechanism. Leuk Lymphoma (2002) 0.77
Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients. Transplantation (2006) 0.77
Different effects of endotoxin versus mite and cat allergen exposure on T-cell differentiation in infants. J Allergy Clin Immunol (2002) 0.77
Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res (2002) 0.76
Immunotherapy in Tumors. Dtsch Arztebl Int (2015) 0.75
Bendamustine and the immune system: a wolf in sheep's clothing? Leuk Lymphoma (2015) 0.75
Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia? Haematologica (2012) 0.75
Allogeneic MHC class I ligands and their role in positive and negative regulation of human cytotoxic effector cells. Hum Immunol (2002) 0.75
[Immuno-Oncology Meets Intensive Care Medicine: CAR-T cells]. Dtsch Med Wochenschr (2019) 0.75
Current use of room disinfectants and allergic symptoms at the age of 4 years. J Allergy Clin Immunol (2009) 0.75